In the above article [Lattard V, Zhang J, Tran Q, Furnes B, Schlenk D, and Cashman JR (2003) Drug Metab Dispos31:854-860], the following errors should be corrected.
On page 856: The sentence “The His132-FMO3 variant (i.e., change of an aspartic acid to a histidine) resulted from a G to T transition at nucleotide position 394.” should be corrected to: “The His132-FMO3 variant (i.e., change of an aspartic acid to a histidine) resulted from a G to C transition at nucleotide position 394.”
On page 856: The sentence “The Pro360-FMO3 variant (i.e., change of a leucine to a proline) resulted from a T to A transition at nucleotide position 1079.” should be corrected to: “The Pro360-FMO3 variant (i.e., change of a leucine to a proline) resulted from a T to C transition at nucleotide position 1079.”
On page 857: In Table 2, first row: “H132(C→ G K158(A→ G M257(A→ G) G308(G→ A) P360(C→ T)” should be corrected to: “H132(G→ C K158(A→ G M257(G→ A) G308(A→ G) P360(T→ C).”
We apologize for any confusion and inconvenience caused by these errors.
- The American Society for Pharmacology and Experimental Therapeutics